Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SEP-363856 in Japanese Schizophrenia Patients
NCT03370640Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ulotaront in schizophrenia (3 cohorts), sponsored by Sumitomo Pharma. Primary endpoint: Frequency of adverse events (AEs), serious adverse events (SAEs), and AEs resulting in study discontinuation at 3 weeks. Started Nov 2017; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03370640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370640.